IRIDEX Corporation (Nasdaq: IRIX) — FY 2019 Form 10-K
Reporting period: Fiscal year ended December 28, 2019 (52 weeks), compared with the year ended December 29, 2018. The filing was signed March 13, 2020. IRIDEX develops and sells ophthalmic laser systems, delivery devices and consumables for glaucoma and retinal disease treatment.
Financial performance and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $43.447 million | $42.600 million |
| Gross profit / gross margin | $17.939 million / 41.3% | $17.471 million / 41.0% |
| Operating expenses | $26.913 million | $30.339 million |
| Operating loss | $(8.974) million | $(12.868) million |
| Net loss | $(8.813) million | $(12.813) million |
| Net loss per share, basic and diluted | $(0.64) | $(1.05) |
| Cash used in operating activities | $(7.913) million | $(10.025) million |
- Revenue increased 2.0%. G6 revenue rose 10.6% to $13.070 million; retina revenue fell 3.5% to $22.879 million; other revenue increased 6.0% to $7.498 million.
- Operating expenses declined across R&D, sales and marketing, and general and administrative functions. Gross margin improved 0.3 percentage points, primarily due to lower manufacturing overhead spending.
- At year-end, cash and cash equivalents were $12.653 million, versus $21.194 million a year earlier; working capital was $20.8 million. The company reported no debt. It used $0.509 million in investing activities and $0.156 million in financing activities in FY 2019.
- In January 2020, the revolving credit facility was amended to provide up to $8.0 million through January 1, 2021, subject to a receivables borrowing base. No borrowings were outstanding at fiscal year-end.
Material changes, outlook and key risks
- Management said existing cash and the available credit line should cover anticipated cash needs for at least the next 12 months. The filing provides no numerical revenue, earnings or margin guidance.
- Management attributed improved cash use partly to higher collections and lower operating expenses. The business remained loss-making and continued to consume operating cash.
- In Q4, IRIDEX released a revised MP3 probe (Rev 2). Initial feedback from approximately 150 physicians was described as positive; this is early customer feedback, not evidence of broad adoption.
- The filing warned that a Wuhan, China manufacturing partner’s work on laser systems planned for release in the second half of 2020 could be delayed or disrupted by the coronavirus outbreak, potentially requiring supplier changes and additional costs.
- A worldwide voluntary recall of the TruFocus LIO Premiere began in 2018 following reports of focal cataracts and iris burns. The company’s March 2019 request to terminate the recall remained pending. The updated device had received FDA clearance, but future safety, adoption and revenue were uncertain.
- Other notable risks include dependence on sole- or limited-source suppliers, international sales (48.7% of revenue), foreign exchange and trade exposure, reimbursement uncertainty, medical-device regulation and competition. The company reported a full valuation allowance against deferred tax assets, citing its loss history and forecasted losses.
- Ordinary-course legal matters were not expected by management to materially affect results. The financial statements received an unqualified audit opinion; management assessed disclosure controls and internal control over financial reporting as effective. The auditor did not attest to internal control effectiveness.
Investor facts to verify
- Whether G6 growth can continue and offset declining retina sales, and whether the revised MP3 probe gains sustained adoption.
- Cash burn, working-capital trends and actual availability of the receivables-based credit line as the company pursues its stated 12-month liquidity outlook.
- Any manufacturing, launch or cost impact from the Wuhan supplier disruption, and the status and consequences of the LIO recall termination request.
- Progress on profitability and gross margin, alongside the effects of lower operating expenses and ongoing product-development needs.
- Regulatory and reimbursement developments, supplier continuity, and the potential realization of tax assets subject to a full valuation allowance.